Topics

MAIT Cell Biology And Cross-Disease Regulation

Intercellular Communication & Diseases Chronic Inflammation Cancer Immunotherapy Metabolic Diseases

Mucosal-associated invariant T cells are abundant innate-like T lymphocytes that link microbial metabolism to rapid tissue immunity. Their semi-invariant T-cell receptor recognizes small molecules presented by the monomorphic MR1 protein, especially intermediates derived from microbial riboflavin synthesis. Because MR1 is minimally polymorphic, MAIT recognition is less dependent on classical HLA diversity. MAIT cells develop through a specialized thymic program, acquire an effector-memory phenotype, and are enriched in blood, liver, lung, intestine, and other barrier tissues. They can kill infected cells, secrete cytokines, recruit other immune populations, and promote tissue repair, with output determined by the tissue and stimulus[1][2].

Activation occurs through more than one route. TCR recognition of MR1-bound microbial ligands provides antigen specificity, while IL-12, IL-18, type I interferons, and related cytokines can activate MAIT cells with limited or no TCR engagement during viral or inflammatory disease. The flexible MR1 pocket can bind structurally diverse molecules, and host-derived bile-acid metabolites have emerged as possible ligands, broadening the biology beyond foreign vitamin metabolites. The consequences of self-ligand recognition remain incompletely defined. Signal strength, costimulation, metabolic state, and prior exposure can shift MAIT cells among cytotoxic, proinflammatory, regulatory, exhausted-like, and repair-associated programs. The same MAIT transcriptional signature can reflect protective antimicrobial activity in one tissue and damaging inflammation in another. Metabolic studies may reveal how nutrient availability, hypoxia, and bile-acid composition influence MR1 ligands or effector programs[1][2][3][4][5].

Disease observations are correspondingly complex. Peripheral MAIT-cell numbers or CD161 expression can fall because cells migrate to tissues, become activated, change markers, die, or are suppressed by corticosteroids. MAIT cells may support antibacterial defense and epithelial repair yet contribute to chronic inflammation through cytokine-only activation or recognition of uncharacterized ligands. Associations have been reported across autoimmune, airway, intestinal, infectious, liver, and malignant diseases, but direction and causality vary. In cancer, checkpoint expression is stimulus dependent: LAG3, PD-1, PD-L1, NKG2A, and TIGIT do not change uniformly across activation conditions. This context must inform any attempt to combine MAIT manipulation with checkpoint therapy. Therapeutic strategies include MR1 agonists or antagonists, cytokine modulation, adoptive MAIT-cell approaches, tissue-repair programs, and checkpoint targeting. MAIT cells are attractive because they are conserved, rapid, and multifunctional, but cross-disease treatment will depend on selecting the appropriate MAIT program rather than globally increasing or suppressing the population. Longitudinal sampling can determine whether low blood counts precede disease, follow tissue recruitment, or result from therapy[1][3][4][5].

Safety requires avoiding cytokine-driven tissue injury, exhaustion, unintended microbial susceptibility, or recognition of healthy tissues. Studies should use MR1 tetramers and functional assays rather than nonspecific markers, sample tissue as well as blood, record corticosteroid exposure, and distinguish TCR- from cytokine-mediated activation. Ligand identity, receptor occupancy, and cellular output should be linked to clinical outcome. Cross-disease comparisons need standardized activation conditions and outcome definitions. Human and mouse MAIT systems also differ in abundance and reagents, so model choice should match the question. Before clinical manipulation, investigators should show that a candidate ligand or antibody produces the intended function in primary human MAIT cells and relevant tissue without broadly activating conventional T cells[1][3][4][5].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-B0240 Disulfiram
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
Aldehyde Dehydrogenase (ALDH)   Interleukin Related   Pyroptosis   Apoptosis   Cuproptosis  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
161
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
87
HY-L084 Microbial Metabolite Library
Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms， which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine. MCE provides a unique collection of 939 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.

Metabolism Focused Libraries Natural Product Screening Libraries

87
HY-L078 Gut Microbial Metabolite Library
Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods. In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 475 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

Metabolism Focused Libraries

85
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L185 Anti-Fibrosis Compound Library
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Disease Focused Libraries

83
HY-L212 Neuropeptide Library
Neuropeptides are small proteins produced and released by neurons through the regulation of secretory pathways, expressed in neurons and have transmitter or co-transmitter functions, and are used as nerve substrates. Neuropeptides are by far the largest and most diverse signaling molecules in the brain and have been implicated in the development of diseases and drugs. Neuropeptides are involved in inflammatory and immune diseases and have an impact on epithelial, vascular, and connective tissue cells proliferation and tissue repair. Studies have shown that neuropeptides are particularly important when the nervous system is challenged, such as stress, injury, or substance abuse. Substance P is a neuropeptide that acts as a neurotransmitter and neuromodulator in the central nervous system and is currently in clinical research and has been shown to be involved in inflammatory processes and pain. MCE can provide 128 neuropeptides that can be used for scientific research.
83
HY-L215 Mass Spectrometry Human Metabolite Library
Metabolomics, positioned as the systemic characterization of small-molecule metabolites within biological systems, has emerged as an indispensable analytical platform in both fundamental research and translational applications across plant sciences, microbial biotechnology, and biomedical investigations. Functioning as a critical component in multi-omics integration, this discipline deciphers the intricate molecular networks operating downstream of genomic, transcriptomic, and proteomic regulation, thereby capturing the dynamic biochemical phenotype closest to organismal functionality. The metabolome, comprising endogenous compounds with molecular weights typically below 1500 Da, serves as the functional readout of cellular processes and environmental interactions, where perturbations in metabolic networks are frequently implicated in disease pathogenesis. Such unique attributes have propelled metabolomics into a pivotal role in pharmacological research, particularly in target deconvolution, pharmacodynamic assessment, and mechanistic elucidation of pathological processes. MCE can provide 6,077 mass spectrometry human metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Metabolism Focused Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
57
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
Dopamine Receptor   Autophagy   Mitophagy   COX   PGE synthase   Interleukin Related   p38 MAPK   Apoptosis   Caspase  
Breast Cancer   Parkinson's Disease  
50
HY-100599 Urolithin A
Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis.

Source: gut bacteria

Drug Metabolite   Reactive Oxygen Species (ROS)   DNA/RNA Synthesis   Autophagy   Apoptosis   Endogenous Metabolite  
Cancer   Digestive System Disease   Digestive System Inflammation  
49
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P1489A OVA Peptide(257-264) TFA
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P1489 OVA Peptide(257-264)
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-12326 c-di-AMP
c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
STING   Bacterial   Endogenous Metabolite  
Inflammation or Immune System Disease  
20
HY-12326B c-di-AMP diammonium
c-di-AMP diammonium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
STING   Bacterial   Endogenous Metabolite  
Inflammation or Immune System Disease  
20
HY-12326A c-di-AMP disodium
c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses.
STING   Bacterial   Endogenous Metabolite  
Inflammation or Immune System Disease  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9926 Dupilumab
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer   Staphylococcus Aureus Infection  
9
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
6
HY-135897 Urolithin C
Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca2+ channel opener and enhances Ca2+ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation.
Calcium Channel   Reactive Oxygen Species (ROS)   Apoptosis   Endogenous Metabolite  
Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation  
5
HY-123941 FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research.
PROTACs   FKBP   Epigenetic Reader Domain   HDAC   Histone Methyltransferase   c-Myc   Polo-like Kinase (PLK)   Ras   MHC  
Leukemia/Lymphoma/Myeloma  
4
HY-Y0520 Itaconic acid
Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect.
Endogenous Metabolite   Ferroptosis  
Cancer   Inflammation or Immune System Disease  
4
HY-B1391 D-Panthenol
D-Panthenol is the biologically-active alcohol of pantothenic acid, which leads to an elevation in the amount of coenzyme A in the cell. D-panthenol exhibits nephroprotective effect in AKI, promotes tissue repair and regeneration.
Environmental Pollutants   Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Glucose Metabolism  
3
HY-W015346 Desaminotyrosine
Desaminotyrosine is a microbially associated metabolite protecting from influenza through augmentation of type I interferon signaling.

Source: Saccharomyces cerevisiae

Influenza Virus   Endogenous Metabolite  
Viral Infection  
3
HY-W050026 Phenylacetylglutamine
Phenylacetylglutamine is a colonic microbial metabolite from amino acid fermentation.
Endogenous Metabolite  
3
HY-D0256A Direct Black 38 free acid
Direct Black 38 (Chlorazol Black E; Ferristatin II disodium) free acid is a benzidine-based azo dye, a substrate of Enterococcus gallinarum, and is mainly used for textile dyeing. Direct Black 38 free acid is biodegradable after being reduced by microbial enzymes (such as Enterococcus gallinarum azoreductase), breaking the azo bonds and releasing benzidine and 4-aminobiphenyl. Direct Black 38 free acid can be used in environmental toxicology, wastewater treatment and carcinogenicity studies, but its metabolite benzidine is listed as a human carcinogen.
Biochemical Assay Reagents  
2
HY-P4846 Ac-Pro-Gly-Pro-OH
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist. Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer.
CXCR   Apoptosis   IFNAR   TNF Receptor   Interleukin Related  
Infection   Allergy  
2
HY-P990131 Anti-Mouse CD47/IAP Antibody (MIAP301)
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis.

Species: Mouse

CD47  
Melanoma   Klebsiella Pneumoniae Infection   Sepsis  
2
HY-D0256 Direct Black 38
Direct Black 38 (Chlorazol Black E) is a benzidine-based azo dye, a substrate of Enterococcus gallinarum, and is mainly used for textile dyeing. Direct Black 38 is biodegradable after being reduced by microbial enzymes (such as Enterococcus gallinarum azoreductase), breaking the azo bonds and releasing benzidine and 4-aminobiphenyl. Direct Black 38 can be used in environmental toxicology, wastewater treatment and carcinogenicity studies, but its metabolite benzidine is listed as a human carcinogen.
Biochemical Assay Reagents  
2
HY-109520 Glatiramer acetate
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
MHC  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
2
HY-W050026S Phenylacetylglutamine-d5
Phenylacetylglutamine-d5 (NSC 203800-d5) is the deuterium labeled Phenylacetylglutamine (HY-W050026). Phenylacetylglutamine is a colonic microbial metabolite from amino acid fermentation.
Endogenous Metabolite   Isotope-Labeled Compounds  
2
HY-P99051 Tinurilimab
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
2
HY-N2406 Dihydrocaffeic acid
Dihydrocaffeic acid is a microbial metabolite of flavonoids. Dihydrocaffeic acid scavenges intracellular ROS and increases nitric oxide synthase activity. Dihydrocaffeic acid reduces phosphorylation of MAPK p38 and prevent UVB-induced skin damage. Dihydrocaffeic acid has antioxidant, anti-inflammatory and anti-cartilage degradation activities.
p38 MAPK   Endogenous Metabolite   Reactive Oxygen Species (ROS)   NO Synthase  
Lung Cancer   Prostate Cancer   Gastric Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
2
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-131166 Curdlan
Curdlan is a polysaccharide found in bacteria, consisting of a glucose homopolymer with β-1,3-glycosidic linkages. Curdlan can be recognized by Dectin-1 (a C-type lectin receptor), inducing immune responses in tissue mast cells and enhancing dendritic cell effects in tumor immunity. Curdlan holds potential for research in cancer and immune-inflammatory diseases.
Bacterial   C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)   NO Synthase   Reactive Oxygen Species (ROS)  
Cervical Cancer   HIV Infection   Bacterial Infection   Autoimmune Disease  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-126855 Cholic acid 7-sulfate
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
G protein-coupled Bile Acid Receptor 1   MHC  
Glucose Metabolism   Obesity  
1
HY-139413 β-D-Glucan
β-D-glucan is a natural non-digestible polysaccharide and high biocompatibility that can be selectively recognized by recognition receptors such as Dectin-1 and Toll-like receptors as well as being easily internalized by murine or human macrophages, which is likely to attribute to a target delivery. β-d-glucan is an enteric delivery vehicle for probiotics.
C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)  
Cancer  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-W015061 Phenylacetylglycine
Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion.
Adrenergic Receptor   Apoptosis   Endogenous Metabolite  
Cardiovascular Disease  
1
HY-P99394 Talquetamab
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

Species: Human

CD3  
Cancer  
1
HY-P99592 Solitomab
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.

Species: Human

CD3  
Ovarian Cancer  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P71133 Serpin E1 Protein, Mouse (HEK293, His)
Serpin E1 protein is a serine protease inhibitor that regulates TMPRSS7 and is a major inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU).It can significantly downregulate fibrinolysis and control thrombus degradation.Serpin E1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Serpin E1 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

Enzymes & Regulators Protease Inhibitors Serpin (Protease Inhibitor) PAI-1

1
HY-P11422 CKS9
CKS9 is an M cell-targeting polypeptide with the amino acid sequence CKSTHPLSC, forming a 9-mer peptide via cyclization through a disulfide bond between the two cysteine residues. CKS9 is obtained through phage display technology screening and has high affinity for M cells. CKS9 can promote chitosan nanoparticles to cross M cells and enter the follicle-associated epithelium (FAE) of intestinal Peyer's patches (PP). CKS9 can be used in studies related to swine dysentery and oral delivery.
Others  
Infection  
/
HY-P11062 M30 peptide
M30 peptide is an MHC class II epitope antigen that can be used in cancer nanovaccine research.
Others  
/
HY-P5254 Hexapeptide-3
Hexapeptide-3isa bioactive peptide with repair skin effect and has been reported used as a cosmetic ingredient.
Others  
Metabolic or Endocrine Disease  
/
HY-P11061 M27 peptide
M27 peptide is an MHC class I epitope antigen that can be used in cancer nanovaccine research.
Others  
/
HY-P11253 DOTA-Bn-CA-170
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
VISTA  
Inflammation or Immune System Disease  
/
HY-P11338 Microcyclamide
Microcyclamide (Compound 1), a cytotoxic cyclic hexapeptide, is a microbial secondary metabolite. Microcyclamide can be isolated from the cyanobacterium Microcystis aeruginosa. Microcyclamide has moderate cytotoxicity against P388 murine leukemia cells with an IC50 of 1.2 μg/mL. Microcyclamide can be used for cancers research.
Endogenous Metabolite  
Cancer  
/
HY-P11249 Mr1.1[S4Dap, C16Pen]
Mr1.1[S4Dap, C16Pen] is a highly active and selective nAChR (human α9α10 nAChR IC50 = 4.0 nM, rat α9α10 nAChR IC50 = 2.7 nM) inhibitor. Mr1.1[S4Dap, C16Pen] can significantly relieve pain and has significant stability. Mr1.1[S4Dap, C16Pen] can be used for the study of neuropathic pain.
nAChR  
Neurological, Eye or Ear Disease  
/
HY-W127357 Tripelargonin
Glyceryl trinonanoate is a triacylglycerol containing nonanoic acid at the sn-1, sn-2 and sn-3 positions. It has been found in Schizochytrium biomass. 1 1,2,3-Trinonanoyl-rac-glycerol increases blood levels of the ketone body D-(-)-3-hydroxybutyrate in neonatal rhesus monkeys. 2|1. Mioso, R., Toledo Marante, FJ, González, JE, et al. Schizochytrium sp. metabolite analysis. Oleaginous microbial sources of biodiesel by GC-MS. braz. J. Microbiology. 45(2), 403-409 (2014).|2. Tetrick, MA, Greer, FR and Benevenga, NJ Blood D- ( )-3-Hydroxybutyric acid concentration. Compare. medicine. 60(6), 486-490 (2010).
Biochemical Assay Reagents  
/
HY-P990270 Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG1. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P11616 WK2
WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection.
Bacterial   TNF Receptor  
Streptococcus Pneumoniae Infection  
/
HY-N0465S Olaquindox-d4
Olaquindox-d4 is the deuterium labeled Olaquindox (HY-N0465). Olaquindox, a quinoxalin derivative, is an orally active antibiotic. Olaquindox stimulates growth and decreases intestinal mucosal immunity of piglets.
Isotope-Labeled Compounds   Antibiotic   Bacterial  
/
HY-W015346S Desaminotyrosine-d8
Desaminotyrosine-d8 (3-(4-Hydroxyphenyl)propionic acid-d8) is the deuterium labeled Desaminotyrosine (HY-W015346). Desaminotyrosine is a microbially associated metabolite protecting from influenza through augmentation of type I interferon signaling.
Isotope-Labeled Compounds   Endogenous Metabolite   Influenza Virus  
/
HY-W713010 3-Epideoxycholic acid-d5
3-Epideoxycholic acid-d5 is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides.
Isotope-Labeled Compounds   Endogenous Metabolite   FXR  
Inflammation or Immune System Disease  
/
HY-N12041 Axl-IN-16
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression.

Source: Hericium erinaceus,Monascus

TAM Receptor   HIF/HIF Prolyl-Hydroxylase  
Cancer  
/
HY-P5681 Human α-Defensin 6
Human α-Defensin 6, a 32-residue cysteine-rich peptide, can inhibit bacterial invasion and contribute to the mucosal immunity. Human α-Defensin 6 forms ordered self-assembly fibrils and nanonets that surround and entangle bacteria after stochastic binding to bacterial surface proteins. Human α-Defensin 6 also inhibits C. albicans biofilm formation.
Bacterial  
Infection   Inflammation or Immune System Disease  
/
HY-W777281 Fluocinolone acetonide-13C3
Fluocinolone acetonide-13C3 is the 13C-labeled Fluocinolone (Acetonide) (HY-B0415). Fluocinolone is a glucocorticoid glucocorticoid receptor agonist. Fluocinolone is effective in preventing both lipid accumulation and inflammation. Fluocinolone can promote the proliferation of DPCs and has the potential role in repairing injured pulp tissues. Fluocinolone can be used to study the prevention of chemotherapy-induced peripheral neuropathy caused by Paclitaxel (HY-B0015).
Isotope-Labeled Compounds   Wnt   Glucocorticoid Receptor  
Metabolic or Endocrine Disease  
/
HY-P10707A Tpp-CAQK TFA
Tpp-CAQK TAF can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK TFA, with excellent bioactivity. Mito-Tpp-CAQK TFA can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury.
Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-P2269 MAIT-203
MAIT-203, a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 binds APC-ARM with a Ki of 0.015 μM and a Kd of 0.036 μM. MAIT-203 significantly represses the migration and invasion of colorectal cancer cells.
Drug Derivative  
/
HY-P991133 Efranarelaxin alfa
Efranarelaxin alfa is a relaxin receptor agonist. Efranarelaxin alfa is promising for research of cardiovascular diseases and tissue repair.
RXFP Receptor  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10707 Tpp-CAQK
Tpp-CAQK can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK, with excellent bioactivity. Mito-Tpp-CAQK can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury.
Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-131557 O-Deacetylravidomycin
O-Deacetylravidomycin, a microbial metabolite discovered in Streptomyces, is an antibiotic. O-Deacetylravidomycin exhibits light-dependent antibacterial and anticancer activities.
Antibiotic   Bacterial  
/
HY-P3529 G-{d-Arg}-GDSPASSK
G-{d-Arg}-GDSPASSK is a polypeptide that prevents cell adhesion, is used for wound healing, and allows tissue repair.
Others  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-126855S Cholic acid 7-sulfate-d4
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
Isotope-Labeled Compounds   G protein-coupled Bile Acid Receptor 1   MHC  
Metabolic or Endocrine Disease  
/
HY-119684S Maresin 2
Maresin 2-d5 is the d5-labeled Maresin 2 (HY-119684). Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury.
Isotope-Labeled Compounds   NOD-like Receptor (NLR)   Interleukin Related  
Digestive System Disease   Anxiety or Fear-Related Disease   Pain   Colitis  
/
HY-N12323 6′-Galactosyllactose
6′-Galactosyllactose is the main oligosaccharide that makes up galactose, a component of human milk. 6′-Galactosyllactose can synthesize human milk oligosaccharides and synthetic galactosyllactose with 3′-Galactosyllactose and 4′-Galactosyllactose, and reduce inflammation in human T84, NCM-460 and H4 cells and intestinal tissues.

Source: Human milk

Others  
Inflammation or Immune System Disease  
/
HY-P992073 OpSCF
OpSCF (INS1148) is an antibody that specifically binds and inactivates inflammatory stem cell factor (SCF), blocks the positive feedback cycle of chronic inflammation, and aids tissue repair. OpSCF can be used for research related to asthma, pulmonary fibrosis, and interstitial lung disease.

Species: Human

Others  
Asthma  
/
HY-W015061S N-(Phenylacetyl-d5)glycine
N-(Phenylacetyl-d5)glycine is the deuterium labeled Phenylacetylglycine. Phenylacetylglycine is a gut microbial metabolite that can activate β2AR. Phenylacetylglycine protects against cardiac injury caused by ischemia/reperfusion.
Adrenergic Receptor   Apoptosis   Endogenous Metabolite  
Blood or Cardio-cerebrovascular Disease  
/
HY-100599S2 Urolithin A-13C6
Urolithin A-13C6 is the 13C-labeled Urolithin A (HY-100599). Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis.
Isotope-Labeled Compounds   DNA/RNA Synthesis   Endogenous Metabolite   Reactive Oxygen Species (ROS)   Apoptosis   Drug Metabolite   Autophagy  
Cancer  
/
HY-P2269A MAIT-203 acetate
MAIT-203 acetate is a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 acetate binds APC-ARM with a Ki value of 0.015 μM and aKd value of 0.036 μM. MAIT-203 acetate significantly represses the migration and invasion of colorectal cancer cells.
Drug Derivative  
/
HY-P990269 Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

Species: Mouse

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P2841 Elastin from pig
Elastin from pig (Elastin) is a key matrix protein that imparts elasticity to organs and tissues. Elastin from pig is a stable, insoluble protein, and utilized in biomaterial for human tissue repairment.
Biochemical Assay Reagents  
/
HY-P2263A KLD-12 TFA
KLD-12 TFA is the TFA salt form of KLD-12 (HY-P2263). KLD-12 TFA is a self a 12-residue self-assembling peptide that is used in tissue-engineering. KLD-12 TFA combined with SDF-1 self-assembled polypeptide enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 TFA hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.
Others  
Inflammation or Immune System Disease  
/
HY-100573S Necrosulfonamide-d4
Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Isotope-Labeled Compounds   Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Integrin   NO Synthase   Heme Oxygenase (HO)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-N2216 Polygalasaponin XXXI
Polygalasaponin XXXI (Onjisaponin F) is an effective adjuvant for intranasal administration of influenza Influenza hemagglutinin (HA) vaccine to protect influenza virus infection.
Influenza Virus  
/
HY-121636S Resolvin D2-d5
Resolvin D2-d5 is the deuterium labeled Resolvin D2. Resolvin D2 is a metabolite of docosahexaenoic acid (DHA), with anti-inflammatory, anti-infective activities. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Resolvin D2 is a remarkably potent inhibitor of TRPV1 (IC50 = 0.1 nM) and TRPA1 (IC50 = 2 nM) in primary sensory neurons.
TRP Channel  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N8693 Withanoside IV
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19).
COX   Amyloid-β   Sirtuin   Reactive Oxygen Species (ROS)   Apoptosis   SARS-CoV  
SARS-CoV-2 Infection   Alzheimer's Disease  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-P991023 Safimestomig
Safimestomig (6MW3211) is an CD47/PD-L1-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer.

Species: Human

CD47   PD-1/PD-L1  
Cancer  
/
HY-P5225 Acetyl hexapeptide-38
Acetyl hexapeptide-38 is a tissue repair promoter that targets fibroblasts in the dermis of the skin. It works by promoting collagen synthesis in the dermis and thickening of subcutaneous fat. Acetyl hexapeptide-38 can activate the skin repair mechanism, increase the collagen content in the dermis, improve the skin tissue structure, and has the activity of promoting local tissue repair. Acetyl hexapeptide-38 can be used in the field of cosmetic medicine to repair congenital soft tissue defects, reduce tear grooves and nasolabial folds, eliminate postoperative scars, and conduct micro-plastic surgery of skin tissue.
PGC-1α  
Digestive System Disease   Digestive System Inflammation  
/
HY-118383 Agathisflavone
Agathisflavone is a flavonoid with antioxidant, anti-inflammatory, antiviral, antiparasitic, cytotoxic, neuroprotective, and hepatoprotective activities. Agathisflavone can improve tissue repair in a spinal cord injury model in rats.
Parasite  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-B1391R D-Panthenol (Standard)
D-Panthenol (Standard) is the analytical standard of D-Panthenol. This product is intended for research and analytical applications. D-Panthenol is the biologically-active alcohol of pantothenic acid, which leads to an elevation in the amount of coenzyme A in the cell. D-panthenol exhibits nephroprotective effect in AKI, promotes tissue repair and regeneration.
Reference Standards   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-P99514 Zalifrelimab
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.

Species: Human

CTLA-4  
Cancer  
/
HY-P2263 KLD-12
KLD-12 is a 12-residue self-assembling peptide that is used in tissue-engineering. KLD-12 combined with SDF-1 self-assembled polypeptide enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.
Others  
Inflammation or Immune System Disease  
/
HY-P99617 Fianlimab
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity.

Species: Human

LAG-3  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer  
/
HY-32955 2-Chloropyridine-5-boronic acid
2-Chloropyridine-5-boronic acid is a mandelate racemase (MR) inhibitor with a Ki value of 8.5 μM against Pseudomonas putida MR.
Bacterial  
Bacterial Infection  
/
HY-Y0669R Pipecolic acid (Standard)
Pipecolic acid (Standard) is the analytical standard of Pipecolic acid. This product is intended for research and analytical applications. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.
Reference Standards   Endogenous Metabolite   YAP   Glutathione Peroxidase   Ferroptosis  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P99917 Eflepedocokin alfa
Eflepedocokin alfa is a recombinant fusion protein. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair.

Species: Human

STAT  
Infection   Inflammation or Immune System Disease  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-N6066 Praeruptorin E
Praeruptorin E is an orally active pyranocoumarin compound. Praeruptorin E can be isolated from the dried roots of Peucedanum praeruptorum Dunn. Praeruptorin E reduces the expression of NF-κB. Praeruptorin E upregulates the expression of PXR and CYP3A4. Praeruptorin E inhibits Th2 cytokines, TNF-α, IL6, MPO, and blocks the Ca2+ slow channel. Praeruptorin E promotes pulmonary tissue repair and relaxes porcine coronary artery strips. Praeruptorin E protects mice from lipopolysaccharide- and hydrochloric acid-induced acute lung injury. Praeruptorin E can be used in studies related to asthma and acute lung injury.
Calcium Channel   NF-κB   Pregnane X Receptor (PXR)   Cytochrome P450   Interleukin Related  
Cardiovascular Disease   Acute Lung Injury  
/
HY-Y0669S Pipecolic acid-d9
Pipecolic acid-d9 is the deuterium labeled Pipecolic acid. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.
Isotope-Labeled Compounds   Endogenous Metabolite   Ferroptosis   YAP   Glutathione Peroxidase  
Infection  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-W019724 2,2-Dihydroxyacetic acid
2,2-Dihydroxyacetic acid is an endogenous metabolite, which is the monohydrate of Glyoxylic Acid. 2,2-Dihydroxyacetic acid may participate in the microbial glyoxylate cycle, induce an increase in reactive oxygen species, promote cell differentiation, and modify proteins to form advanced glycation end products (AGEs) (HY-NP165). 2,2-Dihydroxyacetic acid is associated with metabolic diseases such as primary hyperoxaluria.
Drug Intermediate   Reactive Oxygen Species (ROS)  
Glioblastoma   Organic Aciduria  
/
HY-P99389 Tesnatilimab
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a KD value of 9.2 pM. Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Inflammation or Immune System Disease  
/
HY-P99378 Neihulizumab
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research.

Species: Human

Apoptosis  
Inflammation or Immune System Disease  
/
HY-P990134 Anti-Mouse CD40L/CD154 Antibody (MR-1)
Anti-Mouse CD40L/CD154 Antibody (MR-1) is an anti-mouse CD40L/CD154 IgG monoclonal antibody. Anti-Mouse CD40L/CD154 Antibody (MR-1) reduces the expression of IFN signaling pathway and lowers the level of IFN-β. Anti-Mouse CD40L/CD154 Antibody (MR-1) can prolong the survival time of transplants. Anti-Mouse CD40L/CD154 Antibody (MR-1) can be used for researches on cancer, inflammation conditions and xenotransplantation such as pancreatic cancer and autoimmune cholangitis.

Species: Mouse

TNF Receptor   IFNAR  
Inflammation or Immune System Disease   Pancreatic Cancer  
/
HY-P1827 mTRP-2 (180-188)
mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology.
Tyrosinase   MHC  
Melanoma  
/
HY-P990026 Ulviprubart
Ulviprubart (ABC-008) is a monoclonal antibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM).

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma  
/
HY-159069 Zymosan (ZM), 95%
Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation.
C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)   TNF Receptor   Connexin  
Cancer   Fungal Infection  
/
HY-P3333 KSPWFTTL
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-N2021A Phosphoramidon disodium
Phosphoramidon disodium, a microbial metabolite, is a specific metalloprotease thermolysin inhibitor with an IC50 of 0.4 μg/mL. Phosphoramidon disodium also inhibits endothelin-converting enzyme (ECE), neutral endopeptidase (NEP), and angiotensin-converting enzyme (ACE) with IC50 values of 3.5, 0.034, and 78 μM, respectively.

Source: Streptomyces tanashiensis

MMP   Angiotensin-converting Enzyme (ACE)   Neprilysin   Endogenous Metabolite  
Inflammation or Immune System Disease   Pancreatic Cancer   Pain   Hypertension   Lung Fibrosis  
/
HY-P1939 Cyclo(L-Leu-L-Pro)
Cyclo(L-Leu-L-Pro) is a cyclic dipeptide with broad-spectrum antibacterial, antiviral and antifungal activities. Its biological activity is highly dependent on the stereoconfiguration and is widely present in microbial metabolites. Cyclo(L-Leu-L-Pro) efficiently and specifically inhibits the production of aflatoxin by Aspergillus flavus. The cis configuration of Cyclo(L-Leu-L-Pro) (cis-cyclo(L-Leu-L-Pro)) has broad-spectrum antibacterial activity against multi-drug resistant bacteria and significantly inhibits the influenza A virus H3N2.
Fungal   Bacterial   Influenza Virus  
Infection  
/
HY-171821 PF-08046054
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
Antibody-Drug Conjugates (ADCs)   PD-1/PD-L1  
Cancer  
/
HY-P1587 IRBP (1-20), human
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.
MHC  
Inflammation or Immune System Disease  
/
HY-128746 2,6-Diaminoheptanedioic acid
2,6-Diaminopimelic acid is a endogenous metabolite produced in bacteria and is a component of cell wall. 2,6-Diaminopimelic acid is essential for microbial metabolism and is a potential marker for quantification of microbial proteins .
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P4193 AH1
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P990132 Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair.

Species: Human/Mouse/Rat

CD47  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-P9990 Litifilimab
Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2. Litifilimab induces internalization of BDCA2 receptors on the membrane of plasmacytoid dendritic cells, inhibits the TLR7/TLR9 signaling pathway, and suppresses the production of type I interferons. Litifilimab can be used in the research of systemic and cutaneous lupus erythematosus.

Species: Human

C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)  
Systemic Lupus Erythematosus  
/
HY-P5558 KLTWQELYQLKYKGI
KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair.
VEGFR  
Neurological, Eye or Ear Disease  
/
HY-112137 Trehalose-6,6'-dibehenate
Trehalose-6,6'-dibehenate is an orally active glycolipid. Trehalose-6,6'-dibehenate activates Mincle and inflammasome, inducing IL-1β secretion in a caspase activity-dependent manner. Trehalose-6,6'-dibehenate exerts a Myd88-dependent adjuvant activity. Trehalose-6,6'-dibehenate induces Th-1/Th-17 immune responses.
C-type Lectin-like Receptors (CTLRs)   Caspase   Interleukin Related   MyD88  
Inflammation or Immune System Disease  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P991015 Pasritamig
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-134816 D-Glucan
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism).
C-type Lectin-like Receptors (CTLRs)   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease   Glucose Metabolism  
/
HY-147295 Odetiglucan
Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response.
Toll-like Receptor (TLR)   C-type Lectin-like Receptors (CTLRs)  
Inflammation or Immune System Disease   Metastatic Pancreatic Cancer  
/
HY-P9954 Catumaxomab
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers.

Species: Human

CD3  
Gastric Cancer   Ovarian Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P10408 Candidalysin
Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity
EGFR   MMP   Calcium Channel   NOD-like Receptor (NLR)   ERK   p38 MAPK  
Infection   Inflammation or Immune System Disease  
/
HY-P99392 Teclistamab
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

Species: Human

CD3  
Cancer  
/
HY-P705394 MR1-B2M Complex Protein, Human (Biotinylated, HEK293, His-Avi)

Species: Human; Source: HEK293

Biotinylated Proteins

/
HY-P84718 MR1 Antibody (YA4415)
MR1 Antibody (YA4415) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MR1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84718A MR1 Antibody (YA4415)(PBS only)
MR1 Antibody (YA4415) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MR1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-K0611 Modified Van Gieson Staining Kit

MCE Modified Van Gieson Staining Kit employs Celestine Blue and Mayer’s hematoxylin for nuclear staining, providing clearer and more stable nuclear visualization while facilitating longer preservation of stained sections. Ponceau S is used for collagen fiber staining, offering stable coloration and strong resistance to fading. This method enables effective differentiation between collagen fibers and muscle fibers, and can assist in distinguishing collagen fiber–derived tumors from myogenic tumors to a certain extent. It is also suitable for observing tissue or organ injury, repair processes, and the degree of fibrosis.

Cell Biology Cell Analysis Staining Kit

/

Keywords

MAIT cells | MR1 | microbial metabolites | mucosal immunity | tissue repair | immune checkpoints